PURE Bioscience to Present at the Noble Financial 12th Annual Emerging Growth Investor Conference

Discussion of FDA Approved PURE Control® to Combat Foodborne Illnesses

SAN DIEGO--(BUSINESS WIRE)-- PURE Bioscience, Inc. (OTCQB: PURE), creator of the FDA approved, patented silver dihydrogen citrate (SDC) antimicrobial, announced today the Company will present at the Noble Financial “NobleCon12” Investment Conference on January 19th 2016 in Florida.

Hank R. Lambert, CEO, will present on Tuesday, January 19th at 11:00am EST. Lambert will discuss the two recent FDA approvals of its Food Contact Notifications (FCNs) for SDC antimicrobial use in (a) fresh produce processing and (b) raw poultry processing:

• SDC is a highly effective, non-toxic food safety solution.
  • PURE Control® addresses a $650 million combined US produce and poultry processing aid market.
• SDC test results demonstrate materially significant reduction in Salmonella, Listeria and E. coli contamination in fresh produce; and dramatic reduction of Salmonella contamination in raw poultry.

The presentation will be webcast live with slides (and available for replay) and can be accessed on the Company's website, http://www.purebio.com/investors/events-presentations/.

About Noble Financial, Inc.

Noble Financial Capital Markets, established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media &entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York, Boston and Los Angeles. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous "non-deal" corporate road shows and sector-specific conferences. www.noblefcm.com.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including acceptance of the Company’s PURE Control as a fresh produce processing aid and the Company’s ability to convert successful evaluations into customer orders; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw poultry and raw meat processing; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2015 and its Form 10-Q for the first quarter ended October 31, 2015. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160111005285/en/

PURE Bioscience, Inc.
Hank Lambert, CEO
619-596-8600 ext.103
[email protected]
or
Bibicoff + MacInnis, Inc.
Terri MacInnis, VP of IR
818-379-8500
[email protected]
or
Redwood Investment Group
Tom Hemingway
714-978-4425
[email protected]

Source: PURE Bioscience, Inc.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• DZS Inc. (DZSI) Receives Favorable Nasdaq Listing Decision
• Masonite (DOOR) Shareholders Approve Transaction with Owens Corning (OC)